Long-acting PrEP | APRETUDE (cabotegravir) APRETUDE, long-acting injectable PrEP for HIV-1–negative at-risk adults adolescents weighing at least 77 lbs See Prescribing Info Boxed Warning
What is APRETUDE? | APRETUDE (cabotegravir) APRETUDE (cabotegravir), the 1st injectable PrEP option for HIV-1–negative at-risk adults adolescents weighing at least 77 lbs See Prescribing Info Boxed Warning
Starting APRETUDE | APRETUDE (cabotegravir) Find helpful tips for starting APRETUDE (cabotegravir) for PrEP for HIV-1–negative at-risk adults adolescents weighing at least 77 lbs See Prescribing Info Boxed Warning
FAQs | APRETUDE (cabotegravir) Looking for more information about APRETUDE (cabotegravir)? Find answers to frequently asked questions about APRETUDE See Prescribing Info Boxed Warning
Clinical Trials | APRETUDE (cabotegravir) Find clinical studies of APRETUDE (cabotegravir) vs a once-daily PrEP pill with a diverse patient population See Prescribing Info Boxed Warning
PrEP de acción prolongada | APRETUDE (cabotegravir) APRETUDE es un medicamento recetado que se usa como PrEP del VIH 1 para reducir el riesgo de contraer la infección por VIH 1 en adultos y adolescentes que pesan al menos 77 libras (al menos 35 kg)
Understanding HIV Risk | APRETUDE (cabotegravir) What is the most important thing I should know about APRETUDE? Important information for people who receive APRETUDE for pre-exposure prophylaxis (PrEP) to help reduce their risk of getting human immunodeficiency virus-1 (HIV-1) infection: